Eli Lilly
U.S. pharma major behind Mounjaro and Zepbound — the biggest beneficiary of the obesity-drug boom.
Coverage of Eli Lilly is rising : 9 signals on the latest tracked day, level with its three-week baseline of 9, across 4 domains (up from 2 a week ago). That makes it the #118 most-covered of the 274 concerns we track.
If Eli Lilly matters to your work, coverage is climbing off its baseline — worth a closer-than-usual look this week.
What’s changed
- STAT+: Eli Lilly to allow more patients to apply for special access to unapproved obesity drug · STAT News — All Content · 2026-08-04
- Amplia Therapeutics Partners with Eli Lilly in FAK-KRAS Combination Lung Cancer Trial - smallcaps.com.au · KRAS Mutation Research (Google News) · 2026-08-04
- Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer - Eli Lilly and Company · KRAS Mutation Research (Google News) · 2026-08-03
- Eli Lilly tops new biopharma ranking on launch success, development speed · Fierce Biotech · 2026-07-31
- STAT+: Moderna launches early trial of Ebola mRNA vaccine · STAT News — All Content · 2026-08-06
- Lilly drops another gene therapy trial from $1B Prevail buyout · Fierce Biotech · 2026-08-06
What the reporting says
Across 55 tracked stories from 22 outlets, reporting on Eli Lilly most often describes regulatory approvals (10), acquisition (3), launches or releases (2), military action (2), funding rounds (1), meetings or visits (1).
It shows up alongside FDA (24), Pfizer (13), Gilead (11), KRAS (11), Merck (10), Astrazeneca (9), Bristol Myers Squibb (8), GLP-1 (8).
Two steps out: AI (through FDA, 24 shared stories on the weaker link); Colorectal Cancer (through FDA, 24 shared stories on the weaker link); Immunotherapy (through FDA, 24 shared stories on the weaker link); United States (through FDA, 24 shared stories on the weaker link).
Tracked since May 6, with coverage on 21 separate days — concentrated in Biotech Pharma and Kras Research.